Electrostatic coating of cationic liposomes encapsulating doxorubicin or paclitaxel with a negatively charged bFGF-derived peptide resulted in increased survival of melanoma or prostate tumor-bearing mice over untargeted liposomal formulations, respectively [154]. The gene discussed is FGF2; the disease is melanoma.